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ABSTRACT 
 
 
   Aurora kinases (A, B and C) are frequently amplified and overexpressed in a 
wide variety of cancers, and their up-regulation often correlates with poor 
prognosis. The potential role of these kinases in tumorigenesis indicates that  
they could be appealing target for molecular therapy. Although extensive 
efforts have been done to develop Aurora kinases inhibitors (AKIs), selective 
for A, B or both kinases, so far, none of them have yet been approved by FDA 
due to their severe toxicity. The aim of this study has been to identify novel 
and powerful AKIs, Aurora B kinase inhibitors. 
In living cells, we tested the inhibition of Aurora B kinase by 7 potential novel 
AKIs, called MK1-7, which share a common molecular scaffold, by evaluating 
Serine 10 phosphorylation of Histone H3, a bona fide downstream  target of the 
kinase in HeLa cells. We selected 4 compounds (MK1, 2, 6 and 7), that were 
able to reduce phosphorylation of Histone H3 at 10 nM dose. Then, we 
evaluated the effect of each inhibitor on: cell cycle progression, spindle 
assembly checkpoint (SAC) escape, cell proliferation and viability. Although 
with different efficacy, these 4 MKs perturb cell cycle progression inducing 
polyploidy. In addition, cells treated with the 4 MKs escape from mitosis 
overtaking the SAC checkpoint. These MKs blocked cell growth with an IC50 
ranging from 0.37 to 2.27 nM (MK1 IC50=1,2 nM; MK2 IC50=2,27 nM; MK6 
IC50=0,44 nM; MK7 IC50=0,37 nM). Based on MK7 most powerful efficacy, 
its effect on cell division and viability was more extensively investigated. HeLa 
cells treated with MK7 were positive for apoptotic Annexin V and propidium 
iodide staining and showed an increase in caspase 3 and PARP cleavages, 
indicating induction of apoptosis. Additionally, MK7 treatment caused 
alteration in mitotic spindle formation, chromosome segregation and 
cytokinesis. Finally, we observed that MK7 is able to inhibit growth of A2780 
(human ovarian carcinoma), HL-60 (human promyelocytic leukemia), HCT116 
(human colorectal carcinoma) and 8505-C (human undifferentiated thyroid 
carcinoma) cell lines. In conclusion, our in vitro data have identified in MK7 a 
powerful compound which could be widely used to inhibit Aurora B kinase in 
different cancer types. 
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1.0 BACKGROUND 
 
 
1.1 Cell Cycle 
 
   The cell cycle is the series of events that take place in a cell leading to its 
division and duplication (replication) with production of two daughter cells. In 
cells without a nucleus (prokaryotic), the cell cycle occurs via a process called 
binary fission. In cells with a nucleus (eukaryotes), the cell cycle can be 
divided into three periods: interphase, the mitotic (M) phase, and cytokinesis. 
During interphase the cell grows, accumulates nutrients, duplicates its DNA 
and prepares itself for mitosis and cell division . During the mitosis, the cell 
separates sister chromatides; the cell divides during the final stage, cytokinesis. 
(Figure 1). 
 
 
Figure 1. Stages of the eukaryotic cell cycle.  
The sequential activation of the specific regulatory factors (cyclin and cyclin-dependent 
kinases - Cdks) of cell cycle are indicated. 
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1.1.1 Interphase 
 
   This is the first stage of cell cycle when the cell is engaged in metabolic 
activity and prepares itself for mitosis. Interphase comprises four phases (G0, 
G1, S and G2) and is mainly regulated by the interaction of Cyclins and cyclin-
dependent kinases (Cdks) (Figure 1). G0 phase (G = gap) is a quiescent state in 
which the cell is unable to progress through cell cycle. When stimulated by 
mitogenic growth factors, Cdk4 and Cdk6 interact with D-type cyclins (cyclin 
D1, cyclin D2 and cyclin D3) to form Cdk-cyclin D active complexes. These 
complexes initiate partial phosphorylation of the retinoblastoma protein (Rb) 
that binds to the E2F transcription factors and inactivates its function as 
transcriptional repressor allowing the cell to enter the G1 phase. The G1 phase 
is the major period of cell growth in which the cell synthesizes RNAs, proteins 
and increases its size. In late G1 phase, active Cdk2-cyclin E complexes 
reinforce Rb phosphorylation leading to the release of E2F which participates 
in the expression of genes required for G1 to S phase transition and DNA 
synthesis. Rb hyperphosphorylation corresponds to the restriction point (G1 
checkpoint), in which the cell decides either to pause or to continue cell 
division. Subsequent to G1, the cell enters S phase for DNA synthesis. Finally, 
G2 phase is the period for final DNA repair, rapid growth of organelles as well 
as protein synthesis before initiation of Mitotic phase (M-phase). G2 
checkpoint at the end of this gap determines whether cells can enter mitosis or 
must extend G2 for further cell growth or DNA repair. The Cdk1-cyclin B 
complex is a key regulator of the G2/M transition driving cells into mitosis 
through phosphorylation of many substrates that contribute to chromosome 
condensation, nuclear envelope breakdown and spindle assembly (Enserink et 
al. 2010; Lapenna et al. 2009).   
 
 
1.1.2 Mitosis 
 
   After successful interphase completion, somatic cells go through mitotic 
phase for cell division. Mitosis (nuclear division) is the most dramatic stage of 
the cell cycle, corresponding to the separation of daughter chromosomes and 
usually ending with cell division (cytokinesis). Mistakes in this stage may lead 
to uncontrolled cell division, aneuploidy and genetic instability that lead to 
cancer development. Mitosis is divided into five phases: prophase, 
prometaphase, metaphase, anaphase and telophase (Figure 2).  
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Figure 2 Stages of mitosis 
In M-phase, the cell goes through 5 phases: prophase, prometaphase,  metaphase, anaphase and 
telophase for seperation of chromosomes. Finally, the cytoplasm is divided through cytokinesis 
to form two daughter cells. The specific events of each phase are indicated in the picture. 
 
 
At prophase, chromosome condensation begins, the duplicated centrosomes 
separate, and some mitotic checkpoint proteins, including Bub1 and BubR1, 
are recruited to kinetochores on the chromosomes (Haruki et al. 2001). At the 
entry of prometaphase, nuclear envelope breaks down. Microtubules emerging 
from the centrosomes at the spindle poles reach the chromosomes and attach to 
the kinetochores. During metaphase, the kinetochore-microtubules pull the 
sister chromatids back and forth until they align along the equatorial plate – an 
imaginary plane locating midway between two centrosome poles. The mitotic 
spindle checkpoint is activated by the signals from unattached kinetochores 
that delays progression to anaphase until all sister chromatid pairs are attached 
to the spindle microtubules and properly aligned (Musacchio and Salmon 
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2007). When this checkpoint is turned off, anaphase starts. Within anaphase, 
kinetochores provide the pulling forces which allow two sister chromatids of 
each chromosome to pull apart toward opposite poles. Simultaneously, the 
midzone is organized by a redistribution of different molecules like actin and 
myosin to form the cleavage furrow. Finally, at telophase, chromatids complete 
their movement, a new nuclear membrane is formed around each set of sister 
chromatids and chromosomes start to decondense into chromatin. At the end of 
telophase, a contractile ring called midbody is formed to initiate the process of 
cytokinesis. Cytokinesis is the ﬁnal stage of cell division, which distributes the 
cytoplasm of a parental cell into two daughter cells. The actinomyosin ring 
constricts the plasma membrane in the equatorial region of a dividing cell to 
form a cleavage furrow between the cytoplasmic content of two daughter cells. 
The ingressing cleavage furrow compresses antiparallel microtubules of the 
midzone into a single large microtubule bundle that comprises the core of the 
midbody. A budge-like structure called the stem body is formed in the center of 
midbody. Midbody localizes the site of abscission where the two daughter cells 
will separate at the end of cytokinesis. A recent study (Hu et al. 2012) 
described the relocalization of midzone microtubule-interacting proteins during 
midbody formation. These proteins localize to three different parts of midbody: 
centralspindlin (Mklp1 and RacGAP1) and its partners (Cep55, Arf6 and Ect2) 
accumulate in the budge of midbody; Prc1 and Kif4 colocalize in the dark zone 
– a narrow region on the stem body unstained with tubulin; while CENP-E, 
Mklp1 and Aurora B were observed in the flanking zone, outside of the dark 
zone. Mklp1 interacting with RacGAP1 forms the centralspindlin complex that 
might be required to recognize the antiparallel microtubule structure of the 
stem body (Hutterer et al. 2009). Kif4 localizes to plus-ends microtubules to 
inhibit their dynamics (Hu et al. 2011). Prc1 stabilizes the microtubule overlap. 
Together with Mklp1, Prc1 helps to transport Polo-like kinase 1 (Plk1), a key 
regulator of cytokinesis, on microtubules. Aurora B kinase and Plk1 act as 
master  regulators to ensure proper progression of abscission (Steigemann et al. 
2009). Abscision, the final separation of daughter cells, requires coordination 
of many molecular machines, including endocytic and secretory vesicle 
trafficking proteins as well as ESCRT (endosomal sorting complex required for 
transport) proteins (Hu et al. 2012).  
 
 
1.2 Structures in mitosis: mitotic spindle and centromeres/kinetochores 
 
1.2.1 Mitotic spindle  
 
   The mitotic spindle is a bipolar, self-organizing microtubule-based machine 
that accurately segregates sister chromatids into the daughter cells during cell 
division. The major structural elements of the spindle are microtubule 
polymers, which are nucleated from the two centrosomes, major components of 
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the spindle poles. As the main microtubule-organizing center of animal cells, 
the centrosome participates in the regulation of cell mobility, organelle 
positioning, intracellular transport and mitotic spindle assembly (Lawo et al. 
2012). It comprises a centriole pair surrounded by a matrix of proteins called 
PeriCentriolar Material (PCM) (Figure 3). Centrioles are cylindrical structures 
composed of nine triplets of microtubules, that are required for the formation 
of centrosomes (Nigg et al.  2009). In each centriole pair, there are two unequal 
centrioles in which the older carries appendages that are close to its distal end. 
During S-phase, each parental centriole (mother centriole) is duplicated by the 
formation of procentriole (daughter centriole) at the proximal end. 
Procentrioles then elongate until maximum length at the end of G2 and reach 
full maturation during late G2 and early M phase by the acquisition of 
appendages. At the end of mitosis, centrioles in each pair begin separation in a 
process called centriole disorientation. During centrosome maturation, the 
PCM increases in size and γ-tubulin ring complexes (γ-TuRC) are recruited 
from the cytosol, thereby promoting microtuble nucleation, the key role of 
centrosome. Previous studies only reported about a uniform amorphous 
electron-dense structure of PCM around the centrioles. Recently, by using 3D 
structured illumination microscopy (3D-SIM), the structure of PCM was 
elucidated (Figure 2). It is composed of nine centrosome components (CPAP, 
centrin, CEP120, CEP192, CEP152, CDK5RAP2, NEDD1, TUBG1, PCNT) 
organized in a toroidal manner around the proximal end of mother centriole in 
interphasic cells (Lawo et al. 2012). The key protein in the centrosome that 
nucleates assembly of microtubules is γ-tubulin (TUBG1). Complexes of γ-
tubulin form ring structures that contain 13 γ-tubulin molecules and have 
diameters similar to those of microtubules. These γ-tubulin rings serve as 
nucleation sites for the assembly of microtubules and may remain bound to 
their minus ends. From these points, α/β-tubulin-heterodimers are attached and 
polymerized at their plus end, their parallel arrangement around a hollow core 
form microtubules. 
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Figure 3. Structure of mitotic spindle. 
 Microtubules are nucleated from two centrosomes forming a mitotic spindle for chromosome 
separation in mitosis; (A) Each centrosome is composed of two orthogonally arranged 
centrioles surrounded by an amorphous mass of pericentriolar material (PCM). Each centriole 
comprises nine triplets of microtubles; the older of the two centrioles (mother centriole) has 
two sets of appendages (additional proteins) along the exterior surface. Microtubules are 
nucleated from the γ-tubulin ring complexes (γ-TuRC) contained in PCM. (B) Organized-
structure of PCM in interphase cells. 9 PCM components are indicated (Lawo et al. 2012). 
 
 
1.2.2 Centromere – Kinetochore 
 
   Centromere is the center region of chromosome. Centromeric chromatin is 
epigenetically characterized by the presence of specialized nucleosomes in 
which the canonical histone H3 is replaced by the variant CENP-A 
(centromeric protein –A) (Guse et al. 2011).  HJURP (Holliday JUnction- 
Recognizing Protein) has been identified as a CENP-A chaperone, which 
directly interacts with newly synthesized CENP-A and guides CENP-A for its 
deposition into the centromeric nucleosomes (Dunleavy et al. 2009). The 
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deposition of CENP-A at centromeres is an important marker for the 
recruitment of a group of 16 proteins constituting the centromere-associated 
network (CCAN) (Westermann and Schleiffer 2013). Recent studies have 
elucidated the function of CCAN proteins as an assembly platform for the 
microtubule-binding interface of the kinetochore, called KMN network, 
consisting of KNL1, Mis12 complex and Ndc80 complex. The connection 
between centromeric nucleosomes and microtubules through kinetochore 
enables for the equal chromosome segregation at anaphase. Conventional 
electron microscopy studies indicated that the kinetochore has a layered 
structure with an electron dense inner plate that contacts centromeric 
chromatin, an outer plate that contacts microtubles and a “fibrous corona” 
middle zone that extends away from the outer plate. In recent years, advances 
in biochemical and proteomic approaches have identified the components of 
kinetochore as well as their functions. Thereby, CENP-A and CCAN subunits 
form a core, conserved part in the inner plate of kinetochore. CCAN proteins 
recruit outer kinetochore components (KMN network) that attach to the spindle 
microtubules. In detail, the N-terminal region of CENP-C interacts with Nnf-1 
and more weakly with Nsl1, both subunits of the outer plate Mis12 complex 
(Screpanti et al. 2011; Przewloka et al. 2011). Through the connection with 
KNL1 and Ndc80 complexes, Mis12 complex enhances the binding of 
microtubules to kinetochores. How the microtubules are attached to 
kinetochore? The Ndc80 complex contains four proteins forming two dimers 
Ndc80/Nuf2 and Spc24/Spc25 linked by long α-helical coiled-coil rod 
domains. First, the Hec1/Nuf2 component of the Ndc80 complex attaches with 
the plus-end of microtubule; then the Spc24/Spc25 heterodimer of the Ndc80 
complex interacts with the histone-fold protein Cnn1/CENP-T and Nsl1 of 
Mis12 complex to establish the linkage with the inner kinetochore (DeLuca 
and Musacchio 2012; Malvezzi et al. 2013). Meanwhile, the KNL1 complex is 
composed of Knl1 and Zwint1 (Zwi) proteins. The C-terminal of Knl1 protein 
directly interacts with Nsl 1 (Mis12 complex) and its N-terminal binds 
microtubules. 
 
 
1.3 Control of cell cycle: checkpoints  
 
   In order to minimize mistakes in DNA synthesis as well as to ensure the 
proper segregation of chromosomes during cell cycle, cells have checkpoint 
controls at the specific phase-to-phase transitions. Normally, checkpoints 
consist of at least three components: a sensor for detecting the mistakes, a 
signal generated by the sensor via a signal transduction pathway and finally, a 
responsive element in the cell cycle machinery to prevent cell cycle 
progression until the errors are repaired (Rieder et al. 2011). There are four 
known checkpoint controls during the cell cycle:  the DNA damage and 
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replication checkpoints, the spindle assembly checkpoint (SAC) and the NoCut 
checkpoint (Morgan 2007; Manuel et al. 2009). 
 
 
1.3.1 Damage/replication checkpoints  
 
   During the development of living organisms, DNA damage might happen by 
the impact of various chemical and environmental agents or by errors in DNA 
replication. These mistakes, if not repaired properly, may lead to mutation, 
cancer or cell death. However, from G1 to G2/M, the cells can induce DNA 
repair mechanisms. The DNA damage/replication checkpoints include damage 
sensor proteins such as the Rad9-Rad1-Hus1 (9-1-1) complex and the Rad17–
RFC complex to detect DNA damage, and the MRN complex (Mre11 
Rad50 and Nbs1). In eukaryotes, the MRN/X complex plays an important role 
in the initial processing of double-strand DNA breaks prior to repair 
by homologous recombination or non-homologous end joining.  The sensor 
complexes transduce signals to ATM, ATR, Chk1 and Chk2 kinases that 
finally phosphorylate p53 and Cdc25 for various responsive pathways 
throughout the cell cycle (Figure 4) (Jeremy and Randy 2010). The dominant 
checkpoint response to DNA damage through G1 depends on p53-p21 pathway 
and is responsible for a G1 arrest. Through both ATM and ATR, p53 is 
phosphorylated at serine 15, protected from MDM2-mediated ubiquitilation 
and proteasomal degradation, and stimulates the transcription of p21 
CIP1/WAF1, the inhibitor of cyclin-dependent kinases. As a result, p21 
inhibits Cdk2-cyclin E and thus stops G1/S progression. Simultaneously, in late 
G1, in response to genotoxic stress the ATR-activated Chk1 increases Cdc25A 
phosphorylation accelerating its ubiquitilation and proteolysis, thereby 
inhibiting Cdk2 activation. During S phase, the DNA damage/replication 
checkpoint is related to a Cdc25A dependent pathway. Zhou et al. (2004) 
distinguished 3 types of S-phase checkpoints: the replication checkpoint, the S-
M checkpoint and the intra-S phase checkpoint. The replication checkpoint is 
initiated to delay DNA replication in response to dNTP depletion or DNA 
polymerase inhibition. This checkpoint firstly inactivates Cdk2-cyclin E to wait 
for DNA repair and then, allows cell cycle ongoing (Jares et al. 2000). The S-
M checkpoint is activated when cells end S phase with incomplete replicated 
DNA. In this case, the checkpoint inhibits Cdk1-cyclin B and stops the cell 
cycle. The intra-S phase checkpoint works in response to DNA Double-Strands 
Breaks (DSBs) occurring at any random locus in the genome. DSBs activate 
ATM autophosphorylation that next phosphorylates Chk2. The combination of 
activated Chk2 by ATM and Chk1 by ATR increases Cdc25A phosphorylation 
leading to down-regulation,  thereby inhibiting Cdk2-cyclin A and delaying S-
phase (Zhou et al. 2004). Finally, the G2/M checkpoint prevents cells from 
initiating mitosis if DNA damage occurs during G2 or if cells enter in G2 with 
unrepaired DNA lesions. The G2/M checkpoint inhibits Cdk1-cyclin B, the 
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mitosis-promoting complex, by p53 pathway or through the degradation of 
CDC25C as above mentioned. 
 
         
 
Figure 4 
Activation of the G2/M checkpoint after DNA damage. (Wang et al. 2009) 
 
 
1.3.2 Spindle Assembly Checkpoint  
 
   In order to minimize the mis-segregation of chromosomes and aneuploidy 
during cell cycle, there is a checkpoint control at the metaphase-anaphase 
transition called spindle assembly checkpoint (SAC) (Musacchio and Salmon 
2007). The mechanism of SAC is displayed in Figure 5. SAC activation delays 
the anaphase onset throughout inhibitory activity on Cdc20, a key cofactor of 
APC/C until each chromosome is bipolarly attached to spindle microtubules 
(Nilsson et al. 2008). Briefly, chromosome segregation is mediated by the 
anaphase-promoting complex/cyclosome (APC/C), an E3 ubiquitin ligase that 
normally targets cyclin B for degradation by the 26S proteasome. By inhibiting 
the APC/C, the SAC keeps cyclin B levels high and arrests the cell in 
metaphase until all kinetochores are attached to spindle microtubules. Once 
chromosomes are properly aligned on the metaphasic plate, SAC is turned off, 
the inhibitory complex dissociates and APC/C gets activated initiating the 
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onset of anaphase. At that time, separase will cleave cohesin to resolve sister-
chromatids cohesion for chromosome segregation. Separase is inactivated by 
securin and cyclin B. Thus, when Cdc20 binds and activates APC/C, securin 
and cyclin B are ubiquitylated and degraded. This in turn leads to the activation 
of separase for the dissociation of sister chromosomes. The core spindle 
checkpoint proteins are Mad1, Mad2, BubR1/Mad3, Bub1, Bub3 and Mps1 
which specifically localize at the unattached kinetochores and become depleted 
after the proper microtubule attachment (May and Harwick, 2006). BubR1, 
Bub3 and Mad2, as key factors, directly bind to Cdc20 and form a mitotic 
checkpoint complex (MCC) which can function as an inhibitory complex 
preventing APC/C activity (Karess, 2005; Herzog et al. 2009). Recent studies 
have elucidated how the SAC proteins are recruited to unattached kinetochore. 
KNL1 is an important factor in the kinetochore-based SAC activation 
(reviewed by Foley and Kapoor, 2013). Thus KNL1 is a crucial substrate of 
Mps1 and its phosphorylation by Mps1 creates a docking site for the SAC 
kinase Bub1. Kinetochore localized Bub1 is necessary and sufficient for 
recruiting the SAC protein Bub3. BubR1 localizes at outer kinetochore in a 
Bub3-dependent manner. Additionally, BubR1 also functions as a 
mechanosensor monitoring CENP-E activity (Chan et al. 1999). CENP-E is a 
kinetochore motor protein, involved in the attachment of microtubule to 
kinetochore (Mao et al. 2010). Interaction of CENP-E and BubR1, at the 
unattached kinetochore is thought to stimulate BubR1 activation in the absence 
of microtubule attachments (Mao et al. 2005; Weaver et al. 2003) and 
conversely, inactivate BubR1 activity in the proper attachment of kinetochore-
microtubules (Musacchio et al. 2007). BubR1 is considered to play an 
important role in the inhibition of the APC/C, together with Mad2 (Musacchio 
et al. 2007). The Mad2 attachment to kinetochore requires docking protein like 
Mad1. Mad1, a stably kinetochore bound protein, is essential for Mad2 
kinetochore localization. Interaction between Mad1 and Mad2 results in the 
conformational modification of Mad2 enabling to bind to Cdc20. Mps1 
contributes to the SAC activity by recruiting Mad and Bub proteins to 
unattached kinetochores (Lan & Cleveland, 2010) and by promoting Mad2 
activation (Hewitt et al. 2010; Maciejowski et al. 2010). Furthermore, Mps1 
prevents the dissociation of the inhibitory complex (Maciejowski et al. 2010). 
All these numerous actors playing together integrate kinetochore functions, 
SAC activation, microtubule attachments and SAC silencing to ensure accurate 
timely chromosome segregation (Foley and Kapoor, 2013). Aurora B activates 
the spindle checkpoint in response to a lack of kinetochore tension and 
prevents the activation of APC/C until proper bipolar spindle attachments are 
formed (Hauf and Watanabe, 2004).The balance of kinase and phosphatase 
activities has a crucial role in kinetochore functions and is not fully described.  
In the presence of spindle poison like Taxol, kinetochores are unable to form 
proper attachments to spindle microtubules. This leads to the permanent 
activation of the SAC and prolongation of mitotic arrest for hours. However 
the SAC cannot prevent a slow but continuous degradation of cyclin B that 
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ultimately drives the cell out of mitosis (Brito and Rieder, 2006). Mitotic 
checkpoint slippage leads to 4N-multinucleated cells exhibiting a micronuclei 
phenotype.  
 
       
 
Figure 5: The spindle or metaphase checkpoint. 
(a) The checkpoint monitors microtubule attachment at kinetochores. (Left) The checkpoint 
apparatus assembled on unattached kinetochores (yellow dots) generates an inhibitor signal  
that delays the metaphase–anaphase transition. In this way, the cell has more time for 
establishing proper kinetochore–microtubule connections (red dots) before the onset of 
anaphase. (Right) If the checkpoint mechanism is defective, a cell can enter anaphase even 
with unattached kinetochores, and this can lead to improper distribution of sister chromatids 
(aneuploidy). (b) Chromosome segregation triggered by the APC/C throughout the SAC turn-
off. At microtubule-unattached kinetochores, SAC promotes the formation of a Cdc20 
inhibitory complex, which inhibits APC/C activity. When each chromosome is bipolarly 
attached to spindle microtubules, SAC signaling is turned off, the inhibitory complex 
dissociates; Cdc20 binds to and activates APC/C promoting ubiquitylation of Securins and 
Cyclin B and thus, their degradations (Karess 2005).  
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1.3.3. NoCut Checkpoint (Abscission checkpoint control) 
 
   Cell abscission is the last step of mitosis and it does not occur until all 
chromatids are pulled out of the cleavage plane. In budding yeast and human 
cells, this event is monitored by the NoCut checkpoint, which involves the 
activities of the chromosome passenger Aurora B kinase and Plk1 (Carmena, 
2012; Chen et al. 2012). When the NoCut checkpoint detects the presence of 
chromatins in the cleavage furrow, it is turned on. Active Plk1 phosphorylates 
a centrosomal protein of 55 kDa (Cep55) and prevents its association with the 
midbody (Bastos and Barr, 2010). Cep55, that efficiently bundles 
microtubules, binds to Mklp1 in vitro and associates with the Mklp1 (mitotic 
kinesin-like protein 1)-MgcRacGAP centralspindlin complex in vivo. 
Meanwhile, Aurora B still phosphorylates Mklp1 and prevents furrow 
ingression (Steigmann et al. 2009). Normally, Aurora B activity gradually 
decreases at cytokinesis, to be null upon abscission. If Aurora B is prematurely 
inactivated, the NoCut checkpoint is turned off, leading to the formation of 
binucleated cells (Chen et al. 2012). At the end of mitosis, once chromosomes 
are segregated away from the cleavage furrow, the NoCut checkpoint is turned 
off, Plk1 is degraded allowing the interaction of Cep55 with kinesin Mklp1 at 
the midbody enabling the recruitment of subsequent midbody components for 
the abscission initiation.  In a recent study, Carmena clarified the molecular 
mechanism by which the CPC controls the timing of abscission through 
regulation of ESCRT-III (Carmena, 2012). The ESCRT (endosomal sorting 
complex required for transport) complexes are formed by proteins involved in 
membrane fission events and include six complexes (ESCRT-0, -I, -II, -III, 
ALIX and VSP4) in human. Different ESCRT complexes are recruited 
sequentially to the site of scission, ending with the recruitment of the ESCRT-
III complex that brings about membrane scission. In cytokinesis, after Cep-55 
is associated with kinesin Mklp1, it interacts with Tsg101 (ESCRT-I) and 
ALIX, which in turn recruit ESCRT-III, the complex responsible for the 
abscission activity. ESCRT-III can assemble in filaments around the abscission 
site and makes the membrane curve, eventually driving the final break between 
daughter cells (Carmena, 2012). This study defines a cellular mechanism that 
links centralspindlin to Cep55, which, in turn, controls the midbody structure 
and membrane fusion at the terminal stage of cytokinesis. 
 
 
1.4 Aurora kinases 
 
   Aurora kinases are higly conserved serine/threonine kinases that have been 
recognized as regulators of mitosis, with key roles from mitotic entry to 
cytokinesis (Carmena et al. 2009). The founding member of the Aurora kinases 
is the Drosophila Aurora Kinase that was discovered in a genetic screen to 
identify genes involved in mitotic spindle function (Glover et al. 1995). Fungi 
23 
 
have only one Aurora kinase, IPL1(Increase-in-ploidy)  in S. Cerevisiae (Chan 
et al. 1993)  and Ark1 (Aurora-related-protein)  in S. Pombe (Petersen et al. 
2001). Ark1 is more related to the Aurora B kinases in higher organism. There 
are two Aurora kinases in Caenorhabditis Elegans and Xenopus Laevis called 
Aurora A and B (Schumacher et al. 1998),  while in mammals there is a third 
Aurora gene called Aurora C ( Bischoff et al. 1999). 
 
 
1.4.1 Localization of Aurora Kinases 
 
   Aurora kinases show different cellular localization during mitosis. Aurora A 
localizes on duplicated centrosomes from the end of S phase (as soon as 
centrioles are duplicated) to the beginning of the following G1 phase, and in 
prophase is still there (Carmena et al. 2003). Then, from metaphase to 
anaphase, it associates with microtubules, close to the spindle poles. Aurora A 
concentrates in the midbody during cytokinesis and finally, it is degraded by 
the proteasome in a Cdh1-dependent manner (Castro et al. 2002). 
Aurora B belongs to the Chromosome Passenger Complex (CPC). Such 
proteins localize to the kinetochores from prophase to metaphase and to the 
central spindle and the midbody in cytokinesis (Carmena et al. 2003). In 
particular, in prophase, Aurora B is localized at first in pericentrometic 
chromatins, then along the lenght of the condensing chromosomes and it 
gradually concentrates in the inner centromere at prometaphase. Thus, it 
transfers from chromosome to microtubules, localizes to the spindle midzone 
in anaphase. Finally, like Aurora A, it is associated with the midbody during 
cytokinesis (Adams et al. 2000). Aurora C is also a CPC protein with a similar 
localization as Aurora B; it is localized to centromeres during prophase to 
metaphase and is redistributed to midzone microtubules during anaphase ( 
Sasai et al. 2004; Li et al. 2004). The different localizations of Aurora kinases 
are correlated with their distinct functions during mitosis (Figure 6). 
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Figure 6.  Localizations and functions of Aurora Kinases in mitosis 
(a) Schematic representation of the different  mitotic phase; 
The localization  pattern and functions of Aurora A (b) and B (c): DNA is stained in blue, 
Aurora A/B in red and α-tubulin in green: Aurora A (in red) localizes around centrosomes in 
prophase, on the microtubules near the spindle poles in metaphase and on polar microtubules 
during anaphase and telophase; Aurora B (in red) shows the typical chromosomal passenger 
localization. Aurora B localizes first in pericentrometic chromatins in prophase, concentrates in 
the inner centromere during prometaphase and metaphase, transfers to the central spindle and 
the cell cortex in anaphase, and finally is associated with the midbody during cytokinesis. 
Aurora C shares similar localization and functions of Aurora B. (Vader et al. 2008) 
 
 
1.4.2 Structure and regulation of Aurora kinases 
 
   Aurora A, B and C comprise 403, 344 and 309 aminoacids, respectively. The 
proteins contain an N-terminal domain composed of 39-129 residues, a protein 
kinase domain and a C-terminal domain of 15-20 aminoacids. Like other 
protein kinases, the highly conserved catalytic domain consists of an activation 
loop, a hinge region binding ATP, an hydrophobic pocket and an allosteric site. 
Overall, the three Aurora kinases share high sequence identity. The kinases 
also share high homology between species and are evolutionarily ancient (eg: 
Aurora A shares 82% sequence identity between the human and rodent genes). 
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They also share common ancestral genes in Drosophila and Yeast. The 
functional similarity between Aurora A and B has been demonstrated by 
experiments showing that a single amino acid change in Aurora A, G198N, can 
convey an Aurora B kinase-like activity (Fu et al. 2009).  However, the N-
terminal domains of Aurora A, B and C share little sequence identity and 
confer unique protein–protein interaction abilities among the Aurora kinases 
(Carmena et al. 2003). The activity of Aurora kinases is regulated at multiple 
levels. Aurora A, B and C all contain a key threonine, named the T-loop 
residue, within their kinase domains that must be phosphorylated to allow for 
kinase activity (Figure 7).  This occurs via autophosphorylation of the T-loop 
residue T288 (Aurora A), T232 (Aurora B) or T195 (Aurora C), which is 
driven by clustering of kinase molecole (Bischoff et al. 1998). Transcription of 
Aurora kinases is cell cycle-regulated. Aurora A mRNA typically peaks at 
G2/M with the protein expression peaking slightly later (Kimura et al. 1997). 
The promoter of Aurora A contains specific sequences required for 
transcription in the G2 phase of the cell cycle (Tanaka et al. 2002). The same is 
true for Aurora B: the level of this protein is cell cycle-regulated and its 
activity peaks just after that of Aurora A. The three kinases are differentially 
expressed at high levels in rapidly dividing tissues such as hematopoietic cells 
(A and B) and germ cells (C only) (Su et al. 2004). Conversely, Aurora kinases 
expression is low or absent in most adult tissues due to their lower rates of 
proliferation. Aurora kinases degradation is also highly regulated. All three 
family members contain destruction boxes (D-boxes) recognized by Anaphase 
promoting complex/cyclosome (APC/C), which mediates their proteasomal 
degradation (Figure 7). The APC/C, in conjunction with its specificity factor 
cdc20 homolog 1 (Cdh1), ubiquitylates Aurora A and targets it for degradation 
during mitotic exit (Walter et al. 2000). Moreover, in addition to its D-boxes, 
Aurora A contains a KEN degradation motif and an N-terminal D-Box-
activating motif (Littlepage et al. 2002). Other regulators of Aurora kinases 
degradation have been identified, such as Cdc4/Fbxw7, checkpoint with 
forkhead and ring finger domain (Chfr) and Aurora A-interacting protein. 
Aurora B contains the same D-Box as Aurora A, but it is primarily degraded by 
proteasome alpha-subunit C8 in a proteasome-dependent manner (Shu et al. 
2003). 
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Figure 7. Domains and structure of the Aurora Kinases. 
N-terminal and C-terminal portions contain D-box and KEN regulatory motifs, the central 
kinase domain is important for the catalytic activity. The central domain also includes key 
regulatory motifs, such as the activation loop residue (T-loop). (  Goldenson et al. 2015)  
 
 
In order to develop kinase inhibitors, the structural features of ATP-binding 
sites of Aurora kinases have been elucidated by X-ray crystallography. Most of 
the available data on the ATP binding site are from Aurora A studies, because 
Aurora B itself has not been crystallized in the absence of its inhibitors (Girdler 
et al. 2008; Sessa et al. 2005). The results showed that Aurora A has a peculiar 
DFG (Asp-Phe-Gly) motif in the ATP binding sites that adopts different 
conformations: the active DFG-in and the inactive DFG-out states (Dodson et 
al. 2010; Martin et al. 2012; Liu and Gray 2006). In the active DFG-in 
conformation, the activation loop is oriented away from the ATP site and 
accessibile for phosphorylation. Conversely, in the inactive-DFG state, in 
presence of inhibitors, the phenylalanine side chain points outwards and 
interacts with inhibitors, preventing the phosphorylation of the activation loop 
(Figure 8). 
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Figure 8. Conformational changes of Aurora A activation loop 
The active DFG-in (left) and the inactive DFG-out states (Liu and Gray 2006) 
 
 
In complex with INCENP and an aurora kinase inhibitor (VX-680), the 
structure of Aurora B has recently been determined (Elkins et al. 2012). The 
overall structure of human Aurora B resembles that of human Aurora A with 
the exception of the conformation of the activation loop. The catalytic domains 
of human Aurora A and Aurora B are 76% identical at the primary sequence 
level, and their ATP-binding pockets differ by just three amino acids in which 
Leu215, Thr217 and Arg220 of Aurora A are replaced by Arg159, Glu161 and 
Lys164, respectively, in Aurora B (Dodson et al. 2010). Remarkably, in 
complexes with the same inhibitor, both Aurora kinases showed a significant 
spatial difference of the DFG motif (Figure 9). In Aurora A, the DFG motif is 
arranged with the Phe underneath the αC helix; while in Aurora B, the αC helix 
is moved further out from the ATP- binding site and the Phe residue is side to 
the helix whereas Asp is not well-ordered in the structure (Elkins et al. 2012) 
 
 
 
Figure 9. Comparison of human Aurora A and Aurora B structures.  
(A) Structure of human Aurora B with INCENP stained green and activation loop stained  red. 
(B) Structure of human Aurora A with TPX2 colored in green and activation  loop colored in 
red. (C) Differences in DFG motif between Aurora B (in yellow) and Aurora A (in pink). 
(modified from Elkins et al. 2012). 
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1.4.3 Function of the Aurora kinases 
 
   Even thought the three Aurora Kinases are involved in cell division, the 
specific function of each kinase is different. Indeed, Aurora A but not B or C, 
regulates centrosome maturation and separation and bipolar spindle assembly, 
while Aurora B controls cytokinesis and chromosome bi-orientation as a 
member of the chromosome passenger complex. Aurora C coordinates meiotic 
spindles  in spermatogenesis, while also cooperating with Aurora B to regulate 
mitotic chromosome dynamics. 
 
 
1.4.3.1 Aurora A: a non residential centrosome kinase 
 
   During mitosis, Aurora A interacts with different substrates for its activation 
and regulation, corresponding to its distinct functions. The major function of 
Aurora A is to coordinate centrosome maturation, mitotic entry, separation of 
centriolar pairs, accurate bipolar spindle assembly and alignment of metaphase 
chromosomes. This kinase interacts with different factors. 
Aurora A is activated by its phosphorylation and by the binding of activator 
proteins (Dodson and Bayliss 2012). Recent studies have described several 
activators of Aurora A. The best characterized cofactor is TPX2, a 
microtubule-associated protein involved in bipolar spindle assembly (Dodson 
and Bayliss 2012; Wittman et al. 2000). TPX2 binds  to Aurora A through its 
conserved NH2-terminal domain, and this event induces the activation segment 
of the kinase to move inside its catalytic pocket. In addition, TPX2 also 
protects a crucial phospho-threonine  (threonine 288 in human Aurora A) in the 
activation segment within the protein against protein phosphatase 1 (PP-1) – 
dependent dephosphorylation and inactivation of Aurora A (Bayliss et al. 
2003) (Figure 10). In vivo, activation of Aurora A sinergistically depend on 
(auto) phosphorylation in its activation segment (on threonine 288) and TPX2 
binding (Tsay et al. 2005). The expression, localization and activity of Aurora 
A are consistent with its function as a centrosomal kinase. Aurora A levels are 
low during G1/S phase, but increase in G2, with both function and expression 
peaking in early M phase (Zhou et al. 1998). With respect to localization, it is 
found at the centrosome in mitotic cells from late S and G2 until telophase, but 
also localizes to the spindle throughout mitosis (Krystuniak et al. 2006).  
Functionally, Aurora A regulates the progression of mitosis by phosphorylation 
of multiple substrates, and it promotes mitotic entry by controlling activation of 
Cyclin-B/Cdk-1 (Satinover et al. 2006). Aurora A also activates Polo-like 
kinase-1 (Plk-1) in G2 through direct phosphorylation of Plk-1 (Macurek et al. 
2008).  Other cofactors and substrates include Ajuba, enhancer of filamentation 
1, BORA, TPX2, PLK-1, astrin, growth arrest and DNA damage-inducible 
45α, transforming acidic coiled-coil containing protein 3 (TACC3) and 
centrosomin (Vader et al. 2008). PLK-1, which is also implicated in 
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centrosome maturation, is involved in targeting Aurora A to centrosomes ( 
Lane et al. 1996). Both PLK1 and CDK11 are required for Aurora A 
recruitment and centrosome maturation (Terada et al. 2003). Other important 
functional interactions include the phosphorylation of LATS2, NDEl1 and 
TACC3 by Aurora A to enforce their recruitment to the centrosome and to 
promote centrosome maturation (Toji et al. 2004). 
 
                           
 
 
Figure 10. Regulation of Aurora A 
Aurora-A ,in red, in the unphosphorylated inactive state, in orange in the phosphorylated 
partially active state, and in yellow in the fully active TPX2-bound  phosphorylated state. 
TPX2 is indicated in pink. Without TPX2, the phosphatase PP1 is able to deactivate the kinase 
via dephosphorylation. With TPX2, most phosphorylation sites are accessible to the 
phosphatase, with the exception of the crucial phosphoThr288, which moves to an  inaccessible 
position between the two kinase lobes (Bayliss et al. 2003). 
 
 
1.4.3.2 Aurora B: the chromosome passenger kinase 
 
   Like Aurora A, Aurora B interacts with different substrates corresponding to 
its distinct roles during mitosis. Aurora B is a passenger protein, together with 
INCENP, Survivin and Borealin. These proteins form, together, the 
chromosomal passenger complex (CPC), and Aurora B is the enzymatic 
member of the complex. The expression of CPC members peaks in mitosis, and 
these proteins are interconnetted. Indeed invalidation of the expression of any 
CPC proteins leads to the degradation of the others (Klein et al. 2006). CPC 
complex has a peculiar localization; from metaphase to anaphase, it 
concentrates in the centromere, from where it controls kinetochore tension, and 
then, when the SAC is turned off at anaphase onset, it transfers to the midzone. 
Finally, it concentrates in the midbody and partecipate to the NoCut 
checkpoint. Association with the partner proteins ensures the correct 
localization of the kinase on the inner centromere (Figure 11). 
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Figure 11. Aurora B and CPC complex activation   
(a) Aurora B activation  requires binding to inner centromere protein (INCENP) and 
phosphorylation . Both of these phosphorylation events are catalysed in trans. 
(b) Aurora B activation is coupled to chromosomal passenger complex (CPC) localization. The 
localization module is composed of INCENP, survivin and borealin and targets the CPC to 
histones at the inner centromere and microtubules at the spindle midzone during early and late 
mitosis, respectively. Enrichment of the CPC at these locations facilitates autophosphorylation 
in trans, which leads to full Aurora B activation (Carmena et al. 2012). 
 
 
Two-step mechanism promote the activation of Aurora B: first the kinase binds 
to INCENP through its C-terminal IN-box sequence, and is then 
autophosphorylated at threonine 232 (Thr 232) within its activation loop 
(Honda et al. 2003; Yasui et al. 2004). In the second step, Aurora B 
phosphorylates INCENP at the TSS sequence; in this way it is fully activated. 
Survivin and Borealin, together with INCENP, also partecipate in the right 
localization of CPC to centromeres, through the identification of two specific 
marks present on chromatin: haspin- dependent phosphorylation of histone H3 
on Thr3 (H3-Thr3ph) and Bub1-dependent phosphorylation of histone H2A on 
Thr120 (H2AThr120ph) (Xu et al. 2009). In details, the Bir domain of Survivin 
recognizes phospho-histone H3 (Thr3), allowing its recruitment on chromatin 
(Figure 12). Meanwhile, histone H2A recruitis Shugoshin, another CPC 
member. The concomitance of the two phosphorylations on centromeres 
triggers the specific recruitment of the CPC (Figure 12) (Campbell and Desai 
2013; Kelly et al. 2010). Simultaneously, Mps1 activity enhances H2A-T120ph 
and is also critical for Shugoshin recruitment to centromeres, thereby 
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promoting Aurora B centromeric localization (van de Walls et al. 2012). As 
shown in Figure 12 , when fully activated, Aurora B exercised a retro control 
on Haspin (Wang et al.2011). 
 
             
 
Figure 12.  CPC on centromere. 
Phosphorylations of histone H3 on Thr3 (H3Thr3P) and histone H2A on Thr120 
(H2AThr120P) allows the recruitment of the CPC at the centromere. Survivin (SVN) interacts 
directly with chromatin whereas the stabilization is provided by the interaction of Borealin 
(Bor) with Shugoshin (Sgo1/2). Within the CPC, Aurora B is fully activated and exercises a 
retro control on Haspin (Xu et al. 2009). 
 
 
Besides, there are two other kinases directly involved in the activation of 
Aurora B: the Checkpoint kinase 1 (Chk1) and Tousled-like kinase 1 (Tlk1). 
Chk1 kinase is a major component of DNA damage and DNA replication 
checkpoints. It was recently found to phosphorylate Aurora B on Ser331 during 
unperturbed prometaphase and during spindle disruption by Taxol. This 
phosphorylation is required for optimal phosphorylation of INCENP on its TSS 
sequence, a motif involved in Aurora B full activation (Petsalaki et al. 2011). 
Aurora B is involved in chromosome condensation and cohesion, microtubule 
kinetochore attachment, mitotic spindle checkpoint regulation, chromosome 
segregation and cytokinesis. 
 
Chromosome condensation: 
   Condensation of chromosome into compact structures is essential for the 
accurate segregation of chromosomes and is driven by Condensin complexes 
(Condensin I and II in human cells) (Takemotor et al. 2007; Hirano 2006). 
Depletion of Aurora B impairs the localization of Condensin I on 
chromosomes and consequently, chromosome condensation (Lipp et al. 2007) 
indicating a direct role of Aurora B in this process. Moreover, Aurora B is 
responsible for phosphorylation of histone H3 on Ser10 and Ser28 during late 
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G2/ prophase step of mitosis (Baek 2011). This phosphorylation is crucial  for 
chromosome condensation during mitosis (Wei et al. 1999; Cerutti and Mollan 
2009). Nevertheless, other data demonstrated that histone H3 phosphorylation 
is only required for the initiation rather than the maintenance of condensed 
chromatin state (Van Hoosser et al. 1998). 
 
Chromosome cohesion: 
   Aurora B also controls chromosome cohesion. DNA is replicated during S 
phase and then condenses in G2 phase. The two sister chromatids require a 
cohesion system to keep them together. This is accomplished by a ring-like 
Cohesin complex that consists of Smc1, Smc3, Scc/Rad21 and Scc3/SA 
(Nasmyth and Haering, 2009). The cohesin complex is released from 
chromatin in two steps: along chromatid arms in prophase and finally, at 
centromere in anaphase (Remeseido and Losada, 2013). Aurora B is reported 
to promote the chromosome recruitment of separase for the complete removal 
of cohesin, at anaphase onset (Yuan et al. 2009). 
 
Bi-oriented microtuble-kinetochore attachment 
   In order to ensure the proper chromosome segregation, microtubules must 
attach sister kinetochores to opposite sides of the mitotic spindle (bi-
orientation). Errors such as syntelic attachments (both kinetochores bind 
microtubules from the same pole); merotelic attachments (one kinetochore 
attaches to both mitotic spindle poles) or monotelic attachments (single 
attachment of one kinetochore in two sister chromatids) exert low tension on 
kinetochore-to-pole connection (Figure 13). Aurora B triggers the 
phosphorylation of kinetochore substrates in a tension dependent manner and 
facilitates the bi-orientation of kinetochore-spindle pole connection. Thus, 
Aurora B resolves syntelic attachment by the phosphorylation of an important 
kinetochore-microtubule-capture factor (Dam1-ring complex), which facilitates 
the turnover of kinetochore-microtubule attachments (Keating et al. 2009). 
Similarly, the phosphorylation of Ndc/Hec1 in KMN by Aurora B is observed 
to increase in the merotelic attachment correction (DeLuca et al. 2006). 
Another study shows the enrichment of MCAK (kinesin-13 microtubule 
depolymerase), at points of merotelic attachment, in an Aurora B-dependent 
manner. When MCAK is phosphorylated, depolymerizes the improperly 
attached microtubules (Knowlton et al. 2006).  
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Figure 13.  The model of kinetochore-microtubule attachments. 
Aurora B corrects abnormal mis-attachments such as monotelic, syntelic or merotelic 
attachments and induces bioriented attachments (Giet et al. 2005). 
 
 
Mitotic spindle checkpoint regulation 
   Aurora B also plays a role in spindle assembly checkpoint (SAC). The SAC 
guards the metaphase-anaphase transition. Aurora B activates the spindle 
checkpoint in response to a lack of kinetochore tension and prevents the 
activation of APC/C until proper bipolar spindle attachments are formed (Hauf 
and Watanabe, 2004). Aurora B targets two proteins for this regulation. The 
first is the microtubule-depolymerising kinesin MCAK, whose activity is 
negatively regulated by aurora B (Sampath et al. 2004), and the second is the 
microtubule-destabilizing protein Stahtmin/Op18, whose activity is inhibited 
by Aurora-B phosphorylation in the vicinity of chromosomes (Gadea and 
Ruderman 2006).  
 
Anaphase and Cytokinesis: 
   Upon SAC inactivation, APC/Cdc20 initiates anaphase onset by destruction 
of Cyclin-B and Securin. This event causes a decrease in Cyclin-B-associated 
Cdk1 activity and a resolution of cohesion between sister chromatids 
(Shirayama et al. 1999). At anaphase, Aurora B localizes to both the central 
spindle/midbody and to the cell cortex, to which it is transported via 
microtubules, and regulates cleavage furrow formation (Bringmann 2005).  
Aurora B, on central spindle, contributes to the rapid switch in microtubule 
dynamics during anaphase (Higuchi et al. 2005) and it is also required, during 
telophase, for disassembly of the mitotic spindle (Buvelot et al. 2003). 
During cytokinesis, the cytoplasm is divided into two new daughter cells with a 
single nucleus. Contraction of an actinomyosin ring generates a cleavage 
furrow that divides the cytoplasm in two. It is fundamental that this cleavage 
only forms after segregation of chromosomes. In this phase an important role is 
exerted by RhoA GTPase, which is controlled during cytokinesis by  a central 
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spindle-localised Complex, called centralspindlin. Correct function and 
localisation of centralspindlin depends on Aurora-B activity (Kaitna et al. 
2000). In addition, during anaphase and telophase, Aurora B interacts with 
others proteins, like Vimentin, Myosin II regulatory light chain and Desmin. 
Together, these data clearly point to a central function of Aurora B during 
cytokinesis. 
 
 
1.4.3.3 Aurora C 
 
   The third member of tha Aurora family, Aurora C, is the least studied. This 
kinase is only present in germ cells in the testis, but the protein could not be 
detected in adult tissues, and it is involved in male meiotic cytokinesis 
(Dieterich et al. 2009). Like Aurora B, Aurora C is a CPC protein, and 
localizes on chromosomes from prophase to metaphase and at the midbody 
from anaphase to telophase phase. In tumor cells, it is present at centrosome, 
like Aurora A (Dutertre et al. 2005). The chromosomal region in which the 
Aurora C gene is located is known to be deleted or translocated in certain 
human cancer cell lines but it is unclear whether Aurora C deletion plays a 
causative role in tumorigenesis (Bernard et al. 1998). In conclusion, it is clear 
that Aurora-C plays an important role during spermatogenesis, but conclusive 
proof that it controls cell cycle progression in somatic and/or tumour cells is 
lacking. 
 
 
1.5 Aurora Kinase and Cancer 
 
   Aurora kinases play essential role during mitosis; for this reason changes in 
their signalling could result in mitotic errors and are associated with 
chromosome aneuploidy and genomic instability (Dar et al. 2010). The Aurk A 
gene is located into a region of chromosome 20q13, that is frequently altered in 
human cancers. The Aurora A F31L polymorphism is associated, for example, 
with an increased risk of esophageal, ovarian, non small cell lung and breast 
cancers (Katayama et al. 2003). The role of Aurora A in carcinogenesis has 
been well studied. Several reports have shown that Aurora A can drive cell 
transformation and tumors formation in nude mice (Zhou et al. 1998) while 
others data suggest that overexpression alone is not sufficient to drive 
oncogenesis, and for this reason, others mutations are necessary to cause 
malignant transformation, such as activation of Ras signalling (Tatsuka et al. 
2005). Overexpression of Aurora A is correlated with centrosome amplification 
and formation of multipolar spindle, defects in the separation of centrosome 
that cause formation of monopolar spindle and consequently abortive mitosis 
and tetraploidy (Nigg et al. 2001). Finally, overexpression of Aurora A 
distrupts spindle checkpoint activation by paclitaxel and nocodazole treatment, 
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causing the cells to became resistant to these chemotherapeutic drugs (Anand 
et al. 2003). Based on these strong lines of evidence, the entusiasm of 
exploring anticancer therapeutic target has initially been focused on Aurora A. 
The role of Aurora B in tumorigenesis remains unclear. Aurk B gene is located 
on chromosome 17p13.1, in close proximity to p53 gene. This chromosome 
region has not been associated with amplification in tumors. Many reports 
describe that Aurora B is overexpressed in certain tumor types, such as 
hepatocellular carcinoma (Aihara et al. 2010; Lin et al. 2010), gastric 
carcinoma (Honma et al. 2013), multiform glioblastoma (Zeng et al. 2007), 
ephitelial ovarian cancer (Chen et al. 2009), malignant mesotelioma (Lopez 
Rio et al. 2006), hematological malignancies (Ikezoe et al. 2007), but is not 
clear wether the observed disregulation of the kinase is a mere reflection of the 
high proliferative index of cancerous cells, or whether it is causally related to 
tumorigenesis. How Aurora B overexpression facilitates tumorigenesis is an 
interesting question; high levels of Aurora B are cause of tetraploidy and 
subsequent genomic instability, while in other view, a recent study proposed a 
new pathway in using Aurora B to prevent tumor growth (Sharma et al. 2013). 
In this study, Aurora B is confirmed as a target downstream of V600E B-Raf in 
MAP kinase signaling cascade relating to cell growth. V600E B-Raf is a 
popular target in melanoma cancer treatment but limited by drug resistance. 
Therefore, the inhibition of Aurora B kinase that is described to reduce the 
oncogenic growth of melanoma cells is a good alternative (Bonet et al. 2012; 
Sharma et al. 2013). The involvement of Aurora C in carcinogenesis has been 
the last explored. A few studies showed that Aurora C is overexpressed in 
colorectal, breast and prostate cancer (Sasai et al. 2004). Furthermore, the 
phenotype obtained upon Aurora C overexpression (polyploid cells containing 
abnormal centrosome numbers) is aggravated in the absence of a functional 
p53 (Dutertre et al. 2005). These data suggest that Aurora C might also be a 
target for cancer treatment, especially in the presence of mutated p53. All these 
data suggest that the involvement of Aurora kinases in cancer development 
makes them to be considered as potential targets in anticancer chemotherapy. 
Even though much effort has been made in decreasing cancer mortality, cancer 
is still one of the major causes of death over the world. Up to date, anti-cancer 
therapy mainly relies on surgery, radiation therapy and chemotherapy, which 
can be used alone or in combination. Both surgery and radiotherapy are only 
local treatments and cannot control the metastatic tumors; whereas, 
chemotherapy is a systemic therapy in cancer treatment. Most 
chemotherapeutic anti-cancer drugs used in the clinic today target the cell cycle 
in order to inhibit the over-proliferation state of tumor cells and then inducing 
apoptosis (Lee and Schmitt, 2003). Classical anti-cancer drugs interfere with 
DNA synthesis, DNA damage, or inhibit the function of the mitotic spindle. 
Among them, microtubule-binding drugs are the most exceptionally successful 
chemotherapeutic compounds currently used in the clinic. Traditional 
antimitotic chemotherapeutics, including taxanes and various Vinca alkaloids, 
are currently used to treat patients with breast, ovarian and non-small cell lung 
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cancers (Lister-Sharp et al. 2000; O'Shaughnessy et al. 2013; Socinski et al. 
2013; Ueda et al. 2013). Both types of drugs create unattached kinetochores in 
mitosis by altering microtubule dynamics and cause long-term mitotic arrest. 
However, the drawback of these drugs is that they also inhibit the function of 
microtubules in normal cells. Lowering the blood counts and inducing 
peripheral neuropathies are the most common unwanted side effects. 
Therefore, current attempts not only try to improve novel anti-microtubule 
drugs, but also to develop drugs towards novel mitotic targets such as mitotic 
kinesins, Aurora kinases and mitotic kinases (e.g.  Cdk and Plk inhibitors). 
 
 
1.5.1 Aurora kinase inhibitors 
 
   Aurora kinases have focused attention as potential targets in the development 
of anticancer drugs. Since the kinase domains of Aurora kinases are highly 
homologous, it is difficult to obtain aurora kinase inhibitors that are specific for 
one kinase. Consequently, most inhibitors target multiple Aurora kinase 
members. A series of pan-Aurora kinase inhibitors have been developed and 
have entered clinical trials, as indicated in Table 1. Among pan Aurora 
inhibitors, Tozasertib (VX-680) was the first inhibitor to be tested in clinical 
trials for the treatment of chronic myelogenous leukemia (CML). It targets  the 
three Aurora  kinases in vitro, with IC50 of 0.7, 18 and 4.6 nM for Aurora A, B 
and C respectively (Ikezoe et al. 2007). Preclinical tests reveal that it inhibits 
the tumor growth in prostate (Lee et al. 2006), thyroid (Arlot- Bonnemains et 
al. 2008), ovarian (Lin et al. 2006) and oral squamous (Pan et al. 2008) cancer 
cells line, with IC50 values ranging from 15 to 130 nM. The inhibition of 
Aurora B kinase induces the accumulation of cells arrested in a pseudo- G1 
state with a 4N DNA content or the accumulation of cells with >4N DNA  
content (the latter population representing cells that exit mitosis and 
subsequently proceed through S phase in the absence of cell division). 
Continous proliferation in the presence of aberrant mitosis and failed 
cytokinesis presumably result in cell death (Gizatullin et al. 2006). VX-680 
was reported to induce apoptotic cell death in Aurora A- high primary 
leukemic blast, but not in Aurora A- low acute myeloid leukemia (AML) or in 
normal bone marrow mononuclear cells (BMMCs); this suggest its potentially 
therapeutic use for some leukemia patients (Huang et al. 2008). More 
interestingly, VX-680 showed in vitro activity against Bcr-Abl bearing the 
Imatinib resistant mutations (Giles et al. 2007; Young et al. 2006). 
Unfortunately, development of VX-680 was terminated due to its severe 
toxicity. The other  pan Aurora kinases inhibitors and their clinical trials are 
listed in Table 1. 
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1.5.1.1Aurora A inhibitors 
 
   Studies validating Aurora A as potential therapeutic target have been mainly 
carried out using gene silencing approaches such as siRNA and antisense 
oligonucleotides. These reports showed for the first time that Aurora A- 
specific inhibition by an antisense oligonucleotide resulted in cell cycle arrest 
in the G2/M phase and in the induction of apoptosis. MLN8237 is a recently 
discovered ATP-competitive selective Aurora A inhibitor (40-fold selective for 
Aurora A compared to Aurora B, IC50 4nM) (Kollareddy et al. 2012). 
Treatment of cells with this compound causes defects in bipolar assembly 
resulting in chromosomal segregation abnormalities. In addition cells arrest in 
mitosis due to activation of the mitotic checkpoint. MLN8237 has proven to be 
effective in preclinical AML studies, and have also been tested in CML in both 
preclinical and clinical studies. Others Aurora A inhibitors are elencated in 
table 1. 
 
 
1.5.1.2 Aurora B inhibitors 
 
   Aurora B has been investigated as a potential target in solid tumors, and in 
leukemia. It has been shown that Aurora B is overexpressed in leukemia cells 
of ALL, AML and CLL patients (Walsby et al. 2008). 
Treatment with Aurora B kinase inhibitors induces the accumulation of cells 
arrested in pseudo-G1 state with >4N DNA content or the accumulation of 
cells with >4N DNA content;  the latter population  representing cells that exit 
mitosis and subsequently proceed through S phase in the absence of cell 
division (Gizatullin et al. 2006). Continued proliferation in the presence of 
aberrant mitosis and failed cytokinesis presumably give rise to cells with 
higher DNA content due to an increase of the cell diameter, resulting in 
apoptosis (Gautschi et al. 2008; Keen et al. 2004). 
AZD1152 is a selective Aurora B inhibitor (IC50 0.36 nM). Data on results 
from the first phase I trial in advanced solid tumors were recently reported; 
these studies evaluate the effect of the treatment on colorectal, melanoma, 
prostate and pancreatic cancer, and recently also in leukemic malignancies 
(Schellens et al. 2006) Preclinical studies performed on AML cells lines and 
primary AML samples  show a reduction of cell proliferation and increase cell 
death (Yang et al. 2007).  Others Aurora B inhibitors are elencated in table 1. 
Although Aurora A was initially considered to be the more appealing 
therapeutic target, the validation of Aurora B as a potential drug target revealed 
its equally critical role in carcinogenesis since it was demonstrated that 
pharmacological agents aiming to target either Aurora A or both aurora kinases  
produced a biological response equivalent to Aurora B inhibition alone 
(Mountzios et al. 2008). 
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            Table 1. Aurora kinases inhibitors in clinic 
 
 
1.5.1.3 Combinated therapy with Aurora kinases inhibitors 
 
   Combination of Aurora kinases inhibitors and conventional therapies 
(citotoxic anticancer agents or radiotherapy) are currently under study. For 
instance, MLN8237 enhanced vincristine or docetaxel chemosensitivity in 
aggressive B-cell non-Hodgkin lymphoma (B-NHL) (Mahadevan et al. 2012). 
Similarly, pan-aurora inhibitor SNS-314 also enhanced antitumor activity of 
microtubule-targeting agents in a colon carcinoma model (Vander-Porten et al. 
2009). Treatment with AZD115 was found to be synergistic with a variety of 
chemotherapeutic agents, including irinotecan, docetaxel, vinorelbine, 
gemcitabine, oxaliplatin, and 5-fluorouracil (Nail et al. 2004), and with 
vincristine and topoisomerase inhibitors, in leukemia cell lines (Yang et al., 
2007). Moreover, this compound also potentiates the radiation response in p53-
deficient cancer cells, suggesting synergy with radiotherapy (Tao et al. 2007). 
This suggests that Aurora kinases inhibitors, like many other molecular 
targeted agents, may optimize their efficacy in combination with classic 
chemoterapeutic agents or other molecular therapies, as well as overcoming the 
drug resistance of kinases inhibitors. 
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2.0 AIM OF THE STUDY 
 
 
   The process of cell division is instrumental for the development and 
progression of tumours and targeting cell division has classically been a 
successful antitumour therapy. So far, most antimitotic compounds (such as the 
vinca alkaloids and taxanes) target the mitotic spindle and trigger mitotic 
arrest, but recent efforts have yielded promising compounds targeting 
regulatory proteins during mitosis (Vader and Lens 2008). The Aurora Kinase 
family of mitotic regulators, have received much attention as potential targets 
for novel anti-cancer therapeutics. In the recent years several small molecule 
ATP-competitive inhibitors have been described that target the Aurora kinase. 
Among a large number of agents evaluated preclinically, the pan-Aurora-
Agents AMG900 and AT9283, the Aurora-A and -B targeting agents 
AZD1152, ZM447439, and ENMD2076, the Aurora-A-specific agent 
MLN8237 (alisertib), and the Aurora-B/C inhibitor GSK1070916A have 
progressed towards clinical trials (Niconova et al. 2013; Dees et al. 2012; 
Hardwicke et al. 2009). The most advanced compound, MLN8237 (alisertib), 
is being evaluated in phase II trials for multiple types of cancer and phase III 
trials for the treatment of peripheral T-cell lymphoma (Dees et al. 2011). 
These data are encouraging, suggesting that Aurora kinase inhibitors may have 
real potential as anti-cancer drugs. If inhibiting a single Aurora kinase mediates 
the anti-tumor activity, it may be beneficial to develop selective inhibitors of 
that particular Aurora kinase in order to minimise potential side effects. Thus, 
it would be important to identify more effective anti-Aurora B inhibitors. 
Aim of our study has been to characterize potential Aurora B kinase targeting 
agents in order to identify novel inhibitor of this kinase. For this purpose we: 
 
 tested ability of seven kinase inhibitors (MK1, 2, 3, 4, 5, 6 and 7) to 
inhibit the histone H3 phosphorylation (downstream target of Aurora B 
kinase) in HeLa cells, and we selected four of them (MK1, 2, 6 and 7) 
on the basis of their efficacy; 
 evaluated effect of Aurora B kinase inhibition by MK compounds on 
cell cycle distribution and DNA content; 
 evaluated how Aurora B inhibition induced by MK 1, 2, 6 and 7 
compounds affects taxol- induced SAC activation. 
 studied the effects of the four compounds on proliferation and viability 
of HeLa cells; 
 evaluated the mechanism of cell death following the treatment with 
MK7, which is the most potent of the 4 compounds; 
 analyzed alteration induced by MK7 treatment in mitotic spindle 
formation, chromosome segregation and cytokinesis in HeLa cells; 
 tested the ability of MK7 to inhibit growth and viability of a panel of 
tumoral cell lines. 
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3.0 MATERIALS AND METHODS 
 
3.1 Compounds 
 
Compounds were synthesized in the Li laboratory. For in vitro experiments, 
compounds were dissolved in dimethyl sulfoxide (DMSO) at 10 mM 
concentration and stored at -80°C.  
 
Selectivity profiling 
 
DiscoveRx 442 kinome-wide selectivity profiling was conducted by 
DiscoveRx Bioscience with KinomeScanTM Technology. 
 
 
3.2 Cell Culture 
 
Cell cultures.  
 
HeLa, A2780, HL-60  cells were grown in RPMI 1640 supplemented with 10% 
fetal bovine serum (GIBCO), 2 mM L-glutamine and 100 units/ml penicillin-
streptomycin (GIBCO). 
8505-C cells were grown in DMEM with 10% fetal bovine serum, 2 mM L-
glutamine and 100 units/ml penicillin-streptomycin (GIBCO). HCT-116 cells 
were grown in McCoy’s supplemented with 10% fetal bovine serum (GIBCO), 
2 mM L-glutamine and 100 units/ml penicillin-streptomycin (GIBCO). 
 
Nocodazole and Taxole treatment.  
 
10
5
 cells were seeded in 60 mm dishes and incubated overnight for cell 
adherence. Next day, nocodazole (100 ng/mL) (Sigma) or Taxol (Sigma) were 
added in complete medium and the culture kept for 16 hours. Mitotic cells were 
harvested upon mitotic shake off, washed three times in PBS and then replated 
in fresh media with or without the drug. 
 
Growth Curves. 
 
HeLa, HCT116 and 8505-C cells (10,000/dish) or A2780 and HL-60 cells 
(3,000/dish) were seeded in 60-mm dishes. The day after, different 
concentrations of MK1, MK2, MK6 and MK7 or vehicle, were added to the 
medium and refreshed every 1-2 days. Cells were counted every day (HL-60 
and A2780) or every 2 days (HeLa, HCT-116 and 850-5C).  
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3.3 Protein Analysis 
 
Protein lysates were prepared according to standard procedures. Briefly, cells 
were lysed in a buffer containing 50 mM N-2- hydroxyethylpiperazine-N'-2-
ethanesulfonic acid (HEPES; pH 7.5), 1% (vol/vol) Triton X-100, 150 mM 
NaCl, 5 mM EGTA, 50 mM NaF, 20 mM sodium pyrophosphate, 1 mM 
sodium vanadate, 2 mM phenylmethylsulphonyl fluoride (PMSF) and 1 g/ml 
aprotinin and clarified by centrifugation at 10,000 xg for 15 min.  
Protein concentration was estimated with a modified Bradford assay (Bio-Rad, 
Munich, Germany) and lysates were subjected to Western blot analysis. 
Immune complexes were detected with the enhanced chemiluminescence kit 
(Amersham Pharmacia Biotech, Little Chalfort, UK).  
 
Antibodies 
 
Anti-phospho-H3 (#9701), that recognizes H3 proteins when phosphorylated 
on Ser10, was from Cell Signaling. Anti-H3 (FL-136),  Anti-Cyclin B1 (sc-
594) and Anti-Geminin (sc-8450) were from Santa Cruz Biotechnology (Santa 
Cruz, CA). Monoclonal Anti- -
Cleaved Caspase-3 Asp175 (#9661) that detects endogenous level of the large 
fragment (17/19 KDa) of activated caspase-3, was from Cell Signaling. Anti-
PARP (#9542), that recognize cleaved PARP by Caspase cleavage, was from 
Cell Signaling.  
Secondary antibodies coupled to horseradish peroxidase were from Santa Cruz 
Biotechnology. 
 
 
3.4 Cytofluorimetric Analysis 
 
Cell cycle analysis. 
 
Synchronized cells or unsynchronized cells were either incubated in the 
presence of MK compounds or vehicle. At the indicated intervals, cells were 
harvested by tripsinization and fixed in 80% ethanol over night at -20° C. After 
washing with PBS, cells were treated with RNAse A (100 U/ml) and stained 
with propidium iodide (25 µg/ml) (Sigma) for 30 min. DNA content was 
measured using the BD FACS Calibur (BD Biosciences, US). A total of at least 
10
4
 events were acquired for each experiment. Data were analyzed with the 
Cell Quest software (BD Biosciences, US). 
 
Cell apoptosis assay. 
 
Treated cells were harvested and rinsed with cold PBS once. After 
centrifugation for 10 min, cells were resuspended in 500 ul of 1X  Annexin V 
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binding buffer (#130-092-052; Miltenyi Biotec) and then added 10 ul of 
Annexin V-FITC and 5 ul of propidium iodide. After incubation for 15 min at 
room temperature in the dark, the samples were analyzed by BD FACS Calibur 
(BD Biosciences, US). A total of at least 10
4
 events were acquired for each 
experiment. Data were analyzed with the Cell Quest software (BD Biosciences, 
US). 
 
 
3.5 Viability Assay 
 
For the evaluation of the cytoxic effects of the MK compounds, cells were 
seeded in 96-well plates. After 24 h, the medium was replaced with medium 
containing increasing concentrations of compounds. Three days later, the cells 
were fixed with 50% trichloroacetic acid and stained with 0.4% 
sulforhodamine B in 1% acetic acid. The bound dye was solubilized in 10 
mmol/L unbuffered Tris solution, and the absorbance was determined at 540 
nm in a microplate reader. 
 
 
3.6 Immunofluorescence Staining 
 
For indirect immunofluorescence, cells were fixed in 4% paraformaldehyde 
and permeabilized with Triton 0.2% X-100 (5 minutes on ice), and then 
incubated with anti-
Coverslips were washed and incubated with an Alexa-488 goat anti-rabbit 
antibody (Invitrogen) for 30 minutes at room temperature. After 5 minutes of 
Hoechst counterstaining, coverslips were mounted in Glycerol/PBS (1:1) and 
observed with a Zeiss LSM 510 META confocal microscope (Carl Zeiss). At 
least 300 cells were counted in triplicate. 
 
 
3.7 Statistical Analysis 
 
Unpaired Student’s t test using Instat software program (Graphpad Software 
Inc) was performed to compare cell growth. All P values were two-sided, and 
differences were considered statistically significant at P <.02. IC50 doses were 
calculated through a curve fitting analysis from last day values using the 
PRISM software program (Graphpad Software Inc). To compare tumour 
growth we used an unpaired t-student test (InStat program, GraphPad 
software). P values were statistically significant at P <.02. 
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4.0 RESULTS 
 
 
4.1 Evaluation of MK compounds potency against Aurora B activity in 
HeLa cells 
 
   In order to identify new Aurora B kinase chemical inhibitors, we tested seven 
compounds, MK1, MK2, MK3, MK4, MK5, MK6 and MK7, obtained by 
combinatorial chemistry optimization of a common molecular scaffold, 
provided by Dr Hong-Yu Li (University of Arizona, Tucson, USA). In an in 
vitro kinase assay, these compounds proved to be efficient Aurora B inhibitors 
with an IC50 <10 nM and selective for Aurora A (IC50 >100 nM).  However, 
the Aurora B assay is not sensitive enough to differentiate compounds with an 
IC50 less than 10 nM.   
To provide evidence that these compounds acted as Aurora B inhibitors and 
determine which compounds were most potent, we initially evaluated their 
effect on phosphorylation of Histone H3, a bona fide Aurora B target in HeLa 
cells. Histone H3 is a direct downstream substrate of Aurora B kinase, and its 
phosphorylation on serine residue 10 (pS10-H3) is crucial for cell entry into 
mitosis. To determine whether MK compounds inhibit pS10-H3, cells were 
synchronized in M phase (prophase) with nocodazole (100 ng/ml for 16 hours). 
Thus, by promoting mitotic arrest nocodazole enriches for cells with high 
Aurora B activity and maximal phosphorylation of Histone H3. Upon mitotic 
shake off, cells in M phase were reseeded in nocodazole containing media in 
the presence or not of different concentrations (10, 50 and 250 nM) of anti-
Aurora B compounds for 3 hours. We determined phosphorylation status of H3 
by Western Blotting with Phospho-specific H3 antibody, able to recognize H3 
only when phosphorylated on Serine 10. As shown in Figure 14, compared to 
untreated control cells, in MK1, MK2, MK3, MK4, MK6, and MK7 treated 
cells there was a dose dependent reduction of H3 phosphorylation on S10. In 
particular, all six compounds were able to significantly decrease H3 
phosphorylation already at 10 nM dose, while MK5 did not display any 
significant activity. H3 protein levels were not affected by the treatment, 
demonstrating that the decreased Phospho-H3 (Ser10) signal was due to the 
inhibition of phosphorylation and not to the degradation of total H3 protein. 
We selected MK1, MK2, MK6 and MK7 for further studies for their stronger 
activity at 50 nM dose. 
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Figure 14. MK compounds potently inhibit Aurora B activity in HeLa cell lines. 
HeLa cells were incubated with nocodazole (100 ng/ml) for 16 hours to arrest them in M 
phase. DMSO (NT) or the indicated compounds were added to cell media at different 
concentrations as indicated. Cells were harvested and protein extracts were subjected to 
Western blotting using an antibody against phosphorylated serine 10 of histone H3 as a marker 
of Aurora B kinase activity. H3 and alpha tubulin antibodies were used as a loading control. 
MK1, MK2, MK6 and MK7 displayed the highest activity. 
 
 
4.2 Effect of Aurora B kinase inhibition by MK compounds on cell cycle 
distribution and DNA content 
 
   Aurora B is necessary for correct progression through M phase, mitotic 
spindle attachment to chromosomes and cell division, thereby playing a key 
role in the maintenance of normal ploidy. Therefore, to investigate the effect of 
MK inhibitors on cell cycle, HeLa cells distribution in cell cycle phases, based 
on their DNA content, was analysed by flow cytometry upon cell staining with 
propidium iodide (PI). The cells were synchronized in M phase with  
Nocodazole (100 ng/ml for 16 hours) which prevents polymerization of 
microtubules. Synchronized cells were released in the presence of 10, 50 and 
250 nM of MK compounds or vehicle (DMSO) for 24 hours and then subjected 
to flow cytometry. A graphic presentation of cell cycle phase distribution 
following treatment with MK compounds is shown in Figure 15; Figure 16 
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shows the percentage of the cells in each cell cycle phase. Treatment with MK 
induced a profound change in cell cycle progression. After release of 
nocodazole block, control cells progressed normally throught G1 and S phase, 
showing a cell cycle profile indistinguishable from that of unsyncronized cells 
(data not shown). At 10 nM dose, MK1, MK6 and MK7 compounds arrested 
cells and induced an increase of  the G2/M cell fraction with concurrent 
accumulation of cells with DNA content >4N (polyploid cells). MK2 at same 
dose had no detectable effects. 50 nM dose of MK1, MK6 and MK7  was 
sufficient to induce polyploidy (8N) in the majority of cells, while for MK2, 
this effect occurred only at 250 nM dose.  
 
Figure 15. Effect of MK compounds on cell cycle distribution and DNA content. 
HeLa cells were synchronized in M phase by nocodazole treatment (100ng/ml for 16 h). Upon 
release from nocodazole, cells were incubated with vehicle (NT) or MK1, MK2, MK6 and 
MK7 at the indicated concentrations for 24 h. Cells were then harvested, DNA was stained 
with propidium iodide and samples were analyzed by flow cytometry. N: aploid DNA content. 
MK1, MK6 and MK7 exerted the most potent effects on induction of polyploidy (8N) 
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Figure 16.  Percentage of cells in the different phases of cell cycle upon treatment with 
MK compounds. 
HeLa cells were synchronized in M phase by nocodazole treatment (100ng/ml for 16 h). Upon 
release from nocodazole, cells were treated subsequently with vehicle (NT) or  MK1, MK2, 
MK6 and MK7 at indicated concentrations for 24 h. Cells were then harvested, DNA was 
stained with propidium iodide and samples were analyzed by flow cytometry. This figure 
depicts quantitative analysis of the experiment reported in Figure 15. The histograms depict the 
cell cycle phase distribution: 2N: diploid DNA; 4N: tetraploid DNA content; 8N: octaploid 
DNA content (corresponding to polyploid cells). 
 
 
4.3 Effect of Aurora B kinase inhibition by MK compounds on the spindle 
assembly checkpoint (SAC) 
 
   The proper segregation of replicated chromatids during mitosis requires that 
the two kinetochores on each sister chromatid are attached to the opposing 
spindle poles. This process is strictly controlled and anaphase onset is delayed 
until all chromosomes are bi-oriented and under proper tension (spindle 
assembly checkpoint: SAC). Upon SAC inactivation, APC/Cdc20 complex 
initiates anaphase by promoting degradation of Cyclin B and Securin, causing a 
decrease in Cyclin B-associated Cdk1 activity and resolution of cohesion 
between sister chromatids. In early G1, APC/Cdh1 complex promotes geminin 
degradation in order to allow G1 entry and DNA replication origin licensing by 
recruitment of MCM2/7 complex. The SAC response activated by either 
unattached kinetochores or by lack of tension on kinetochores has been studied 
by using microtubule-destabilizing (Nocodazole) or microtubule- stabilizing 
(Taxol) drugs, respectively. Whereas both treatments cause a SAC-dependent 
mitotic arrest, Aurora B is required for the arrest in response to Taxol, but less 
essential for the arrest induced by Nocodazole (Biggins et al. 2001; Carvalho et 
al. 2003). 
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We asked therefore whether Aurora B inhibition induced by MK compounds, 
was able to suppress Taxol-induced SAC activation. Hela cells were treated 
with Taxol (100 ng/ml) for 16h and then replated in media containing Taxol  
plus MKs at different concentrations (10, 50 and 250 nM) for 5 hours. In order 
to monitor SAC escape with consequent mitosis exit and entry in G1, Cyclin B 
and Geminin protein levels were evaluated by Western blotting. As shown in 
Figure 17, MK compounds were able to induce Cyclin B and Geminin 
degradation in a dose dependent manner suggesting an overcome of Taxol-
induced SAC and an inappropriate mitosis exit. In particular, at 50 nM MK1 
and MK2 induced Cyclin B degradation and at 250 nM Geminin degradation, 
while MK6 and MK7 induced Cyclin B degradation already at 10 nM and 
Geminin degradation at 50 nM (Figure 17). 
 
     
 
Figure 17. Effect of MK compounds on Taxol-dependent activation of the spindle-
assembly checkpoint (SAC). 
HeLa cells were treated with Taxol (100 ng/ml) for 16 hr to arrest them in M phase and then 
with the indicated concentrations of MK compounds for 5 hr. Cells were harvested and protein 
extracts were subjected to Western blotting with the indicated antibodies to assess M phase exit 
(Cyclin B degradation) and subsequent G1 phase entry (Geminin degradation). Tubulin 
staining was used as a loading control. 
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4.4 Effect of MK compounds on cell proliferation and viability 
 
   Since Aurora B plays a key role in cell cycle progression, its inhibition could 
result in defects in cell proliferation. We performed cell growth curves of HeLa 
cells treated with MK compounds. Cells were treated with MK1, MK2, MK6 
or MK7 at different concentrations (10 pM, 0.1-1-10-50 nM) for six days and 
counted every two days, using the vehicle alone as control. As shown in Figure 
18, all the four compounds were able to reduce proliferation of HeLa cells. In 
particular, MK6 and MK7 were the most effective compounds, inhibiting 
proliferation with an IC50 of  0.44 and 0.37 nM respectively, while MK2 was 
the least effective one with an IC50 of 2.3 nM. MK1 displayed an intermediate 
efficacy, with an IC50 of 1.2 nM. The lower IC50 dose displayed by MK 
compounds in growth curves with respect to biochemical Aurora B kinase 
inhibition (see Figure 14) raised the possibility that cell treatment caused a 
cytotoxic rather than a cytostatic effect. 
 
 
 
Figure 18 Effect of MK compounds on cell proliferation. 
Top) HeLa cells were incubated with DMSO (NT) or with the indicated concentrations of MK 
compounds in 10% fetal bovine serum. Cells were counted at the indicated time points. Data 
are the mean ± SD of two experiments performed in triplicate. Bottom) Growth inhibition IC50 
of MK compounds for HeLa cells.  
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We explored this possibility by measuring cell viability via Sulforhodamine B 
assay. Based on the high efficacy of MK7, we selected this drug for such an 
experiment and thereafter. HeLa cells were seeded in 96-well culture plates and 
allowed to grow for 24 hr followed by MK7 treatment for 3 days. As shown in 
Figure 19, 10 nM MK7 showed a potent cytotoxic effect, reducing viable cells 
to 60% of the control. 
 
 
 
Figure 19 Effect of MK7 on cell viability. 
HeLa cells were subjected to Sulforhodamine assay to detect viable cells upon treatment with 
vehicle (NT) or the indicated concentrations of MK7. Viable cells were plotted as percentage 
of control. Experiment was performed in triplicate and SD are indicated; *** p< 0.001 
compared to NT. 
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4.5 Evaluation of cell death induced by MK7 
 
   Since MK7 treatment resulted in a decrease of cell viability, we explored the 
mechanism of cell death upon MK7 treatment. Apoptosis, or programmed cell 
death, is an essential mechanism used by multicellular organisms to negatively 
select cells that are deemed deleterious to the host. Typical apoptosis is 
distinguished from necrosis as only the former involves the activation of 
specific pathways that result in characteristic morphological features including 
DNA fragmentation, chromatin condensation and formation of apoptotic 
bodies. Many stimuli can trigger various pathways to apoptosis, but all these 
pathways converge to a common process involving the activation of a cascade 
of caspases that specifically cleave protein substrates at aspartic acid residues. 
One of the distinct early cellular changes during apoptosis is 
phosphatidylserine translocation from the internal to the external portion of the 
cellular membrane. Annexin V-FITC is a fluorescent probe which detects early 
apoptosis by binding to externalized phosphatidylserine in the presence of 
calcium and can be detected by flow cytometry. Staining of cellular DNA with 
propidium iodide (PI) in the absence of cellular permeabilization allows 
detection of cells whose membrane has been totally compromised as it occurs 
in late apoptotic stages or in necrosis. Thus, live cells show no staining with 
either Annexin V-FITC or PI. Cells which are early apoptotic will stain only 
with the Annexin V-FITC. Late apoptotic cells are stained by both Annexin V-
FITC and PI. Finally, necrotic cells stain with PI only. HeLa cells were treated 
with MK7 (0.01, 0.1, 1.0 and 10 nM) for three and six days, followed by 
staining with Annexin V-FITC/PI and analysis by flow citometry. As shown in 
Figure 20, percentages of cells in late (upper right panel) apoptosis increased 
parallel to increasing concentration and duration of exposure  to MK7. 
At 10 nM concentration, late apoptotic cells were 31% after three days of 
treatment, and 57% after six days, compared to 4% and 1.9% in the untreated 
control cells. Interestingly, after 6 days of treatment late apoptotic cells already 
increased by more than 2 fold at a dose as low as 0.01 nM and more than 4 fold 
at 0.1 nM. After 3 and 6 days of treatment necrosis was also detected but only 
at 10 nM (Figure 20). Apoptosis following MK7 treatment was also confirmed 
by Western blotting to detect Caspase-3 cleavage by Caspase-9 and PARP 
(Poly ADP-Ribose Polymerase) cleavage by Caspase-3. As shown in Figure 
21, both apoptotic markers were increased in a dose dependent manner 
following MK7 treatment, compared with the untreated control. These data 
support the notion that treatment with MK7 resulted in the accumulation of 
polyploid cells that subsequently undergo apoptosis-mediated cell death. 
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Figure 20. Cell death induced by MK7 in HeLa cells. 
A) HeLa cells were treated with vehicle (control) or MK7 at the indicated concentrations for 3 
or 6 days. Cell death was detected by ﬂow cytometric analysis based on propidium iodide (y-
axis; necrosis), annexin V staining (x-axis, early apotosis) or both (late apoptosis). B) 
Percentages of cells displaying different types of cell death are shown in the bar graphs. 
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Figure 21. Western blotting analysis of PARP and Caspase 3 Cleavage after MK7 
treatment 
HeLa cells were treated with MK7 at indicated concentrations for 72 hr. Cells were harvested 
and protein lysates were subjected to Western Blotting with the indicated antibodies to detect 
apoptosis. Tubulin staining was performed as a loading control. 
 
 
4.6 Effect of MK7 on mitotic spindle and on cell division 
   To analyze effects of MK7 treatment on mitotic spindle formation, 
chromosome segregation and cytokinesis, Taxol-synchronized HeLa cells were 
released in MK7 (10 and 50 nM) containing medium for 2 hours, fixed in 
paraformaldeyde and incubated with anti-tubulin antibody to detect mitotic 
spindles and with Hoechst to analyze chromatin structure by fluorescence 
microscopy. Cells treated with 10 nM dose exhibited only a few kinetochore-
attached microtubles and were unable to organize the ordered mitotic spindle 
that was seen in control cells. As a consequence, chromosomes could not be 
fully separated and cells prematurely escaped mitosis as shown by chromatin 
decondensation before chromosome segregation. Furthermore, chromosomes 
appeared to be either splayed out throught the cell, or, rather than aligning at 
the spindle equator, lined up along the fibers of the spindle (Figure 22). 
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Figure 22. Immunofluorescence staining of mitotic spindle in MK7 treated cells.  
Exponentially growing HeLa cells were synchronized with Taxol in M phase (100 ng/ml), then 
released from M phase arrest and treated with 10 or 50 nM MK7 or vehicle (NT). After 2 hr, 
cells were fixed and stained by immunofluorescence with anti- -tubulin (green) to visualize 
polymerized microtubules and Hoechst (cyan) to visualize chromatin at different time points. 
 
 
4.7 Effect of MK7 on proliferation of a panel of human tumor cell lines 
 
   We evaluated the effects of MK7 on viability of a panel of different 
neoplastic cell lines. To this aim, we selected four human cell lines, derived 
from different tumor types: A2780 (human ovarian carcinoma), HL-60 (human 
promyelocytic leukemia), HCT116 (human colorectal carcinoma) and 8505-C 
(human undifferentiated thyroid carcinoma). Initially, we performed cell 
growth curves. HCT-116 and HL-60 cells were treated with MK7 at different 
concentrations (0.1, 1, 10 and 50 nM) for six and four days, respectively, using 
the vehicle alone as control. Instead, 8505-C and A2780 cells, were treated by 
1, 10 and 50 nM dose of MK7, because preliminary experiments showed that 
0.1 nM of the drug was poorly effective (data not shown). As shown in Figure 
23, all the cell lines were sensitive to MK7, with an IC50 in the same range as 
that calculated for HeLa cells. In particular, HCT-116 and HL-60 showed an 
IC50 of 0.475 nM and 0.490 nM, respectively. 8505-C and A2780 cell growth 
was inhibited with IC50 values of 1.451 nM and 1.571 nM, respectively.  
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Figure 23 Effect of MK7 on cancer cell proliferation. 
Top) Cells were incubated with DMSO (NT) or with the indicated concentration of MK7 in 
10% fetal bovine serum. Cells were counted at the indicated time points. Data are the mean 
±SD of two experiments performed in triplicate. Bottom) Cell growth inhibition IC50 of MK7. 
In brakets, 95% confidence intervals are indicated. 
 
 
Then, we measured cell viability upon MK7 treatment via Sulforhodamine B 
assay in A2780, HCT116, 8505-C and HL-60. Cells were seeded in 96-well 
culture plates and allowed to grow for 24 hours, followed by MK7 treatment 
for three days at concentrations of 10, 50 and 250 nM. As shown in Figure 24, 
of the four cancer cell lines analysed, the A2780 cell line was the most 
sensitive to MK7 treatment. In details, 3-days incubation of A2780 cells with 
MK7 at 10 nM reduced viable cells to 20% of the control. In the same 
experimental conditions, treatment of  HCT-116, 8505-C and HL-60 cells 
reduced cell number by approximately  20, 30 or 40%, respectively.  
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Figure 24. Effects of MK7 on cell viability. 
Cells were subjected to Sulforodamine assay to detect viable cells upon treatment with vehicle 
(NT) or the indicated concentration of MK7. Viable cells were plotted as percentage of control. 
Experiment was performed in triplicate and SD are indicated; *** p< 0.001; ** p< 0.05; * 
p<0.3. 
 
 
4.8 Kinase selectivity of MK7  
 
   In order to evaluate the specificity of MK7 compound we performed a 
kinome scan selecting 96 kinases distributed throughout the AGC, CAMK, 
GMGC, STE, TK, TKL, lipid and atypical kinase families (scanEDGE, 
Discoverex) at a concentration of 300 nM. The scan mapped 11 interactions 
with a binding score < 35% of the control and only 2, including Aurora B, with 
a binding score < 1% of the control (Aurora B and CSF1R), indicating high 
selectivity (Figure 25). 
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Figure 25. Kinome wide selectivity profiling of MK7. 
Data were generated with DiscoveRx Treespot Version 4. Red dots indicate % of binding at 
300 nM concentration of drug compared to DMSO control. S-score (35) indicated the 
selectivity when threshold was set at ≥ 65% binding. The size of the red circles is proportional 
to the strength of the binding, e.g. large circles imply high affinity. 
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5.0 DISCUSSION 
 
 
   The process of cell division is instrumental to the development and 
progression of tumours. Targeting  the structural components of the mitotic 
machinery is a consolidated strategy in the treatment of cancer. Microtubule-
binding agents, such as taxanes or vinca alkaloids, are strongly active against a 
variety of human cancer types, but MDR (multiple drug resistance), that limits 
the efficacy of many current anticancer therapies, as well as general and 
specific side effects (e.g. peripheral neuropathy) remain persistent problems. 
Consequently, there is a need for novel antimitotic drugs that target non-
microtubule proteins, such as the mitotic kinases, that might display less severe 
side effects. The Aurora kinases have been frequently found to be 
overexpressed in many types of human tumors, and, as key mitotic regulators,  
have shown to be promising clinically relevant targets  In the recent years, 
several small molecule ATP-competitive inhibitors have been describe, 
including VX680 (pan Aurora kinases inhibitor), AZD1152 (Aurora B 
inhibitor)  and MLN8237 (Aurora A inhibitor). More than 30 small molecule 
Aurora kinase inhibitors are currently in different stages of preclinical and 
clinical development, however none have yet been approved by the U.S. Food 
and Drug Administration for clinical use.  
Here, we describe preclinical analysis of seven compounds, MK1, MK2, MK3, 
MK4, MK5, MK6 and MK7, obtained by a common molecular scaffold, in 
order to identify a novel powerful Aurora B kinase inhibitor. In an in vitro 
kinase assay, these compounds proved to be efficient Aurora B inhibitors with 
an IC50 <10 nM and selective for Aurora A (IC50 >100 nM). In this study we 
show that four MK compounds (MK1, 2, 6 and 7) are able to decrease the 
phosphorylation level of Histone H3 at Ser 10 at nanomolar concentration in 
HeLa cells. These 4 compounds perturb the normal progression of cell cycle, 
cause an overcoming of taxol-induced SAC and promoting an inappropriate 
mitotic exit. In addition they efficiently block proliferation. In particular, one 
of them, MK7, is the most effective with an IC50 dose comprised between 0.37 
and 2 nM. In details, MK7 treatment induces apoptosis and causes alterations 
in mitotic spindle formation, chromosome segregation and cytokinesis. Starting 
from these data and based on the high efficacy of MK7, we test the effects of 
this molecule on viability of a panel of different neoplastic cell lines 
demonstrating its efficacy in blocking proliferation of  variuos types of cancer 
cells. 
It is important to note some limitations of the studies described in this thesis. 
Firstly, we evaluated the effectiveness of MK7 on tumoral cell lines, but we 
didn’t describe the effect on normal cells. We might expect that MK7 does 
affect normal cell viability as well, being an important component of the 
mitotic machinery. Nevertheless, due to their high mitotic index and 
aneuploidy, cancer cells are more dependent on the correct functioning of 
proteins regulating chromosome partition and cell division compared to normal 
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cells, a phenomenon known as non-oncogene addiction. This consideration 
indicates a greater sensitivity of cancer cells to Aurora kinase inhibitors with 
respect to normal cells. In addition, in order to increase efficacy and selectivity 
of action on cancer cells, combination regiments of Aurora kinase inhibitors 
and conventional therapies (citotoxic anticancer agents or radiotherapy) might 
represent a breakthrough and are currently under study. For instance, 
MLN8237 enhanced vincristine or docetaxel chemosensitivity in aggressive B-
cell non-Hodgkin lymphoma (B-NHL) (Mahadevan et al. 2012). Similarly, 
pan-aurora inhibitor SNS-314 also enhanced antitumor activity of microtubule-
targeting agents in a colon carcinoma model (Vander-Porten et al. 2009). 
Treatment with AZD115 was found to be synergistic with a variety of 
chemotherapeutic agents, including irinotecan, docetaxel, vinorelbine, 
gemcitabine, oxaliplatin, and 5-fluorouracil (Nail et al. 2004), and with 
vincristine and topoisomerase inhibitors, in leukemia cell lines (Yang et al., 
2007). Moreover, this compound also potentiates the radiation response in p53-
deficient cancer cells, suggesting synergy with radiotherapy (Tao et al. 2007). 
In summary, these data indicate that Aurora kinases inhibitors, like many other 
molecular targeted agents, may optimize their efficacy and specific action on 
cancer cells in combination with classic chemoterapeutic agents or other 
molecular therapies. 
Another important limitation of our study is the lack of in vivo data; with this 
respect, an important point is the choice of formulation. Oral administration 
certainly improves drug compliance for patients. Many of the existing agents 
have been developed as intravenous drugs and only the Aurora A inhibitor, 
MLN8054, is available in oral formulas. Nevertheless, it should be noted that, 
although oral administration seems to be much more convenient for the 
patients, it is generally correlated with a greater variation in pharmacodynamic 
parameters and particularly with an unpredictable bioavailability. Moreover, 
since neutropenia has been, thus far, the major dose-limiting toxicity in this 
class of compounds, it appears that intermittent parenteral formulation may 
constitute the optimal choice. Chemical properties of  MK7 compound allows 
us to predict its possible use via an oral formulation (data not shown). 
Therefore, further experiments are needed to test the pharmacokinetics and 
pharmacodynamics properties  of MK7 and whether it would be effective as a 
drug given per os and which might be the best administration regiment, also in 
light of assessing its possible toxic effect and off target activity. 
In spite of these limitations, our findings suggest that MK7 represent a 
promising selective inhibitor of Aurora B kinase. 
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6.0 CONCLUSION 
 
 
   Here, we describe MK7, a promising  powerful compound which could be 
widely used to inhibit Aurora B kinase in several tumor cell lines.  
At first we tested seven compounds, MK1-7 that shared a common molecular 
scaffold. In an in vitro kinase assay, these compounds proved to be efficient 
Aurora B inhibitors with an IC50 <10 nM and selective for Aurora A (IC50 
>100 nM). 
Briefly,  we performed a series of experiments in HeLa cells to determine 
which compound is most potent. Our data demonstrate that MK7, in Hela cells, 
is able to: reduce phosphorylation of Histone H3 at 10 nM dose and perturb 
cell cycle progression inducing polyploidy already at 50 nM. Treatment with 
MK7 also promote escape from mitosis overtaking the SAC checkpoint and 
block cell growth with an IC50 of 0.37nM. Our data demonstrate also that MK7 
has effect on cell  division and viability, and promote cell death by apoptosis. 
Additionally, MK7 treatment caused alteration in mitotic spindle formation, 
chromosome segregation and cytokinesis. Finally, MK7 is an efficient Aurora 
B kinase inhibitor in several cancer cell lines. Further studies will assess the 
efficacy of MK7 compound in in vivo settings.  
In conclusion we reckon that MK7 is a potent novel Aurora B kinase inhibitor 
which deserves important attention for its potential use in patients, upon its 
testing in preclinical models to assess efficacy, toxicity and best administration 
modality. 
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